Clinical assessment of Siddha medicine â??MADHUMEGA NIVARANI CHOORANAMâ?? for the management Fof TYPE II DIABETES MELLITUS

PHASE II NON RANDOMIZED OPEN CLINICAL EVALUATION OF SIDDHA MEDICINE â??MADHUMEGA NIVARANI CHOORANAMâ?? FOR THE MANAGEMENT FOR â??MADHUMEGAMâ?? (TYPE II DIABETES MELLITUS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/11/047298

Enrollment

Registered

2022-11-15

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: MADHUMEGA NIVARANI CHOORANAM: It is an Siddha herbal drug for the management of Type 2 DM.It will be given in oral route as the dose of 2gm(BD) with warm water for the duration of 60day

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with age between 30-60 years Sex: All Gender Polyuria Polyphagia Polydipsia Blood glucose(F) - >= 126 mg/dl (14) Blood glucose (PP) - >= 200 mg/dl (14) HbA1C - >= 6.5% (14) On two or less than two diabetes medication

Exclusion criteria

Exclusion criteria: Pregnant women Lactating mothers Insulin dependent Diabetes Mellitus Cardiovascular disease Diabetic nephropathy Diabetic retinopathy T.B affected individuals HbA1c > 10%

Design outcomes

Primary

Measure	Time frame
Outcome is mainly assessed by Reduction in clinical symptoms like Polyuria, Polyphagia, Polydipsia, and Fatigue. Timepoint: 4 weeks	—

Secondary

Measure	Time frame
Reduction in blood sugar and HbA1C level (at least 20%) Timepoint: 10 weeks	—

Countries

India

Contacts

Public ContactN SURESH BALAJI

Government siddha Medical college

nanbu.sumi@gmail.com9443279412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026